This is a working overview of dose escalation, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-06-17. Anything still debated is marked as such rather than presented as settled.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Several questions remain unresolved. It is not yet known whether the compound reduces cardiovascular events or mortality, because outcome studies require long follow-up. The durability of weight reduction after treatment withdrawal is uncertain, and rebound has been observed with other incretin-based therapies. Long-term safety data covering several years are limited. Effects in adolescents, in pregnancy, and in people with significant kidney or liver impairment have not been characterized in published reports.
Randomized studies of retatrutide measure change in body weight as a percentage of baseline, along with absolute weight loss. Glycemic endpoints include hemoglobin A1c and fasting plasma glucose. Investigators also track blood pressure, lipid fractions, and liver fat content to characterize effects beyond weight alone. Trial designs typically use double-blind, placebo-controlled groups with periodic dose escalation, and they record adverse events throughout both treatment and follow-up periods.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Interpretation depends on study phase and duration. Phase 2 programs are powered for weight and safety signals, not for cardiovascular or renal outcomes, which require event-driven designs. Gastrointestinal events such as nausea, diarrhea, vomiting, and constipation are the most frequently reported adverse effects and tend to cluster around dose escalation. Small increases in heart rate have been described. Because follow-up after treatment discontinuation is limited, questions about weight regain and durability are open rather than answered.
Trial reports for this compound rely on a small set of repeated measures. Body weight is normally expressed as percent change from baseline at a fixed week, with absolute kilograms given secondarily. Glycemic endpoints include HbA1c, fasting glucose, and, in some protocols, continuous glucose monitoring summaries. Imaging endpoints such as MRI-derived proton density fat fraction quantify liver fat. Standardization matters because a percent change and a categorical responder analysis can tell different stories about the same dataset.
The benefit of ACE inhibitors extends even to those who have to commence dialysis to treat their kidney disease, and may give sufficient benefit to allow the discontinuation of renal replacement therapy.
=== Value of tracking symptom occurrence === The appearance of these signs and symptoms can not only provide clues for the diagnosis of an autoimmune condition, often in conjunction with tests for specific biological markers, but also help monitor disease progression and response to treatment. Ultimately, due to the diverse nature of autoimmune diseases, a multidimensional approach is often needed for the management of these conditions, taking into consideration the variety of symptoms and their impacts on individuals' lives.
=== Preventing recreational opioid use === Naloxone is poorly absorbed when taken orally or sublingually, so it is often added to oral or sublingual opioid preparations, including buprenorphine and pentazocine, so that when swallowed or taken sublingually, only the non-naloxone opioid has an effect. However, if the combination is injected (such as by dissolving a pill or sublingual strip in water), the naloxone is believed to block the effect of the other opioid. This combination is used to prevent non-medical use. However, SAMHSA's clinical guidelines state that if the combination of buprenorphine and naloxone is injected by a regular user of buprenorphine or buprenorphine/naloxone, then the buprenorphine would still produce an agonist effect but the naloxone would fail to produce an antagonist effect. This is because the amount of naloxone that would be required to block the buprenorphine after injection is much larger than the amount that is contained in buprenorphine/naloxone (Suboxone) pills and strips. If someone who is not physically dependent on opioids were to inject the buprenorphine/naloxone combination, then the effects of the buprenorphine may at most be slightly lessened, but the individual would still be expected to experience euphoric effects.
== Medical uses == Chlorprothixene's principal indications are the treatment of psychotic disorders (e.g. schizophrenia) and of acute mania occurring as part of bipolar disorders. Other uses are pre- and postoperative states with anxiety and insomnia, severe nausea / emesis (in hospitalized patients), the amelioration of anxiety and agitation due to use of selective serotonin reuptake inhibitors for depression and, off-label, the amelioration of alcohol and opioid withdrawal. It may also be used cautiously to treat nonpsychotic irritability, aggression, and insomnia in pediatric patients. An intrinsic antidepressant effect of chlorprothixene has been discussed, but not proven. Likewise, it is unclear if chlorprothixene has genuine (intrinsic) analgesic effects. However, chlorprothixene can be used as co-medication in severe chronic pain. Also, like most antipsychotics, chlorprothixene has antiemetic effects.
Primary: Sodium thiopental, 5 grams, intravenous Secondary: Midazolam, 10 mg, intramuscular; sufentanil, 450 micrograms, intramuscular; and/or hydromorphone, 40 mg, intramuscular In the brief for the U.S. courts written by accessories, the State of Ohio implies that they were unable to find any physicians willing to participate in the development of protocols for executions by lethal injection, as this would be a violation of medical ethics, such as the Geneva Promise, and such physicians would be thrown out of the medical community and shunned for engaging in such deeds, even if they could not lawfully be stripped of their license. On December 8, 2009, Kenneth Biros became the first person executed using Ohio's new single-drug execution protocol. He was pronounced dead at 11:47 am EST, 10 minutes after receiving the injection. On September 10, 2010, Washington became the second state to use the single-drug Ohio protocol with the execution of Cal Coburn Brown, who was proclaimed dead within two minutes after receiving the single-drug injection of sodium thiopental. Eight states (Arizona, Georgia, Idaho, Missouri, Ohio, South Dakota, Texas, and Tennessee) have used the single-drug execution protocol. The state of Washington used this single drug method only once, as it later abandoned the death penalty. Four additional states (Arkansas, Kentucky, Louisiana, and North Carolina) announced that they would switch to a single-drug protocol but, as of June 2025, had not executed anyone since switching protocols.
Sources: en.wikipedia.org
2024 Greater Manchester mayoral election: Labour's Andy Burnham secures a third term as Mayor of Greater Manchester with almost two-thirds of the votes cast. The SDLP announces that it will change the way it makes "civil leadership" appointments following the resignation from the party of two Derry City and Strabane District Council councillors over the appointment of Lilian Seenoi-Barr as the authority's next mayor. 5 May – With all votes counted, the results from the local elections in England are: Labour 1,158 (+186), Liberal Democrat 522 (+104), Conservative 515 (−474), Independents and others 228 (+93), Green 181 (+74), Residents' Association 48 (+11), Workers Party of Britain 4 (+4), Reform UK 2 (+2). 6 May – Argentina's president, Javier Milei, tells the BBC he accepts the Falkland Islands are currently "in the hands of the UK", but says his country will get them back through diplomatic channels. John Swinney is confirmed as Leader of the Scottish National Party after being unopposed in the leadership election, and begins his second tenure in the post. 7 May – John Swinney wins the backing of the Scottish Parliament to become Scotland's seventh First Minister, and will be sworn into office the next day. The Green Party's Siân Berry, who was re-elected in the 2024 London Assembly election, is criticised for resigning three days later to hand her seat to Zoë Garbett, who lost in the same election with 5.8% of the vote.
The chemistry of plutonium was found to resemble uranium after a few months of initial study. Early research was continued at the secret Metallurgical Laboratory of the University of Chicago. On August 20, 1942, a trace quantity of this element was isolated and measured for the first time. About 50 micrograms of plutonium-239 combined with uranium and fission products was produced and only about 1 microgram was isolated. This procedure enabled chemists to determine the new element's atomic weight. On December 2, 1942, on a racket court under the west grandstand at the University of Chicago's Stagg Field, researchers headed by Enrico Fermi achieved the first self-sustaining chain reaction in a graphite and uranium pile known as CP-1. Using theoretical information garnered from the operation of CP-1, DuPont constructed an air-cooled experimental production reactor, known as X-10, and a pilot chemical separation facility at Oak Ridge. The separation facility, using methods developed by Glenn T. Seaborg and a team of researchers at the Met Lab, removed plutonium from uranium irradiated in the X-10 reactor. Information from CP-1 was also useful to Met Lab scientists designing the water-cooled plutonium production reactors for Hanford. Construction at the site began in mid-1943. In November 1943 some plutonium trifluoride was reduced to create the first sample of plutonium metal: a few micrograms of metallic beads. Enough plutonium was produced to make it the first synthetically made element to be visible with the unaided eye.
The members of Es La Guerilla wanted to move in a different musical direction, but had rehearsed very little with Kévone, the band's singer, before entering the recording studio. Kévone was less interested in the band's new direction. After a while, Nackphouminh tried his hand at singing.
=== Albania === On 21 December 2024, Albanian Prime Minister Edi Rama announced that the Albanian government will shut down TikTok in 2025 for at least a year, following a deadly incident in November 2024 in which a teenager fatally stabbed another teen after a dispute that began on the platform. On 7 March 2025, the shutdown was officially enacted after the Albanian Cabinet cited concerns over the app's role in promoting violence and bullying among children.
Sources: en.wikipedia.org
The parenteral route is any route that is not enteral (par- + enteral). Parenteral administration can be performed by injection, that is, using a needle (usually a hypodermic needle) and a syringe, or by the insertion of an indwelling catheter. Locations of application of parenteral administration include:
== History == B&K Corporation Limited was founded in 2012 in Qingdao, China, and commenced research and development of PDGF drugs in 2013. The company subsequently established a research and development centre in Beijing and a laboratory in Hong Kong. Between 2021 and 2023, the company completed three financing rounds, raising a total of approximately RMB405 million. Investors included Qingdao High-Tech and CDH Investment. Following the Series B round in 2023, the company's post-money valuation reached RMB3.3 billion. In July 2026, the company officially changed its Chinese name from "華芢生物" to "青城新藥".
== Further reading == Panzer-Heinig, Sabine (2009). Antithrombin (III) - Establishing Pediatric Reference Values, Relevance for DIC 1992 versus 2007 (Thesis). Medizinische Fakultät Charité - Universitätsmedizin Berlin.
=== Other uses === Ammonium sulfate is a precursor to other ammonium salts, especially ammonium persulfate ((NH4)2S2O8. Ammonium sulfate is listed as an ingredient for many vaccines by the Centers for Disease Control. Ammonium sulfate has also been used in flame retardant compositions acting much like diammonium phosphate. As a flame retardant, it increases the combustion temperature of the material, decreases maximum weight loss rates, and causes an increase in the production of residue or char.
== Risk factors == Adolescents are the most vulnerable group when it comes to taking performance-enhancing substances. This is in part due to the significance placed on physical appearance by this age group as well as feelings of invincibility combined with a lack of knowledge surrounding long-term consequences. Studies have shown that the most common gendered risk factors include being an adolescent female dissatisfied with their body weight or an adolescent male who perceives larger body sizes as the ideal. Having a negative body image or a history of depression can also be a significant risk factor. These are further exacerbated by parental pressures surrounding appearance, media influence, and peer pressure. Studies show that adolescent males who engage with fitness magazines are twice as likely to use performance-enhancing substances. Adolescents who partake in competitive sports are at a particularly high risk, with those involved in gridiron football, basketball, wrestling, baseball, and gymnastics at the top.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
Trials measure percentage change in body weight, absolute weight loss, and glycemic markers such as hemoglobin A1c. They also record blood pressure, lipids, and liver fat. Adverse events are tracked throughout.